FDC Limited is a renowned Indian pharmaceutical company that has been in operation for over 85 years. Founded in 1936, the company has emerged as a leading player in the healthcare industry, specializing in the development, manufacturing, and marketing of a wide range of pharmaceutical products. FDC’s business can be broadly categorized into three segments: prescription drugs, over-the-counter (OTC) products, and oral rehydration salts (ORS). The company offers a diverse portfolio of prescription medicines, catering to various therapeutic areas such as gastroenterology, cardiology, respiratory, and dermatology. These prescription drugs are trusted by healthcare professionals and patients alike for their efficacy and quality.
- FDC Limited reported Total Income for Q4 FY23 of ₹441.85 Crore up from ₹350.72 Crore year on year, a growth of 26%.
- Total Expenses for Q4 FY23 of ₹396.74 Crore up from ₹331.75 Crore year on year, a growth of 19.6%.
- Consolidated Net Profit of ₹30.66 Crore, up 195% from ₹10.39 Crore in the same quarter of the previous year.
- The Earnings per Share is ₹1.85, from ₹0.62 in the same quarter of the previous year.